AzTrials
AzTrials

UrolithiasisSTONENCT04594161

Effectiveness of Drainage by PCN vs. JJ in Patients With Symptoms of Obstructive Kidney Disease Caused by Urolithiasis

A study testing Percutaneous Nephrostomy and Double J catheter in people with Urolithiasis and Urologic Diseases, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 1 site in Netherlands.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To investigate the effectiveness of percutaneous nephrostomy catheter placement versus retrograde double J catheter placement in patients with symptoms of obstructive kidney disease (with either infection and/or pain and/or kidney function deterioration) caused by urolithiasis. Read more about this study

Who is it for?
Any age
Conditions the study is for
Urolithiasis, Urologic Diseases, Urinary Calculi
What is being tested?
Percutaneous Nephrostomy and Double J catheter
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
204 participants
Where
1 siteNetherlands
Study dates
15 Jul 2020to 1 Jan 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • In order to be considered eligible to participate in this study, a subject must meet all of the following criteria:
  • Male/female >18 year
  • Symptoms and/or laboratory results indicating obstructive kidney disease with or without infection.
  • A kidney or ureteral stone is present on ultrasound or CT (max 3 months old prior to presentation)
  • Both drainage techniques are feasible and safe in opinion of the treating physician (from logistics point of view and in the best interest of the patient).
  • Willing and able to comply with filling in questionnaires and follow-up regiment

Who cannot join

  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • Analphabetic or not mastering the Dutch language
  • Pregnancy
  • Usage of anticoagulation agents other than acetylsalicylic acid.
  • Contraindication for either technique looking at history and anatomy (e.g. kidney transplant, pouch, Bricker deviation, urethral or ureteral stenosis)

Trial locations and contacts

1 site in 1 country.

Netherlands1 site
  • Amsterdam UMC, location AMC

    Amsterdam, North Holland, 1105 AZ

Other trials in Netherlands

About this study

Official title: Effectiveness of Drainage of the Kidney by Percutaneous Nephrostomy Catheter Placement Vs. Retrograde Double J Catheter Placement in Patients With Symptoms of Obstructive Kidney Disease Caused by Urolithiasis

To investigate the effectiveness of percutaneous nephrostomy catheter placement versus retrograde double J catheter placement in patients with symptoms of obstructive kidney disease (with either infection and/or pain and/or kidney function deterioration) caused by urolithiasis.

Read the detailed description

SUMMARY Rationale If a stone obstructs the ureter and impairs urine-efflux from the kidney this may cause infection, pain resulting from a renal colic and/or renal impairment. Drainage of the kidney may be necessary and can be established by placement of either a percutaneous nephrostomy (PCN) or a retrograde double J catheter (JJ). Considering method of drainage, setting, room in which drainage procedures takes place and anesthesia method, there are in fact 16 different approaches for drainage available, each with its own consequences for the patient and on expenses. Although evidence is poor, both methods of drainage are to be considered as equal.[1] This is reflected by the differences in preference between different countries.[2] In 2016 the Dutch association for urology (Nederlandse Vereniging voor Urologie (NVU)) marked this subject as one of the primary knowledge gaps in urology in The Netherlands and gave it priority on the national knowledge agenda for urology.[3] From patients' as well as from societal perspective it is of importance that the decision for placement of either PCN or JJ will be made based on evidence based arguments and in a uniform way.

Hypothesis: Percutaneous nephrostomy is non inferior to retrograde double J catheter regarding time to clinical recovery. Secondly, patient reported outcome measures (PROMS) comparing treatment room and OR settings of drainage procedures will most likely not be significantly different.

Finally, because percutaneous nephrostomy catheters are more often placed in a (outpatient) urological or radiological treatment room, this is expected to be less expensive than placement of a double J catheter (more often placed in the OR). Objective: To investigate the effectiveness of percutaneous nephrostomy catheter placement versus retrograde double J catheter placement in patients with symptoms of obstructive kidney disease (with either infection and/or pain and/or kidney function deterioration) caused by urolithiasis.

Study design: Multicenter prospective randomized controlled non-inferiority trial.

Study population: Male and female adult patients with signs of obstructive kidney disease with kidney or ureteral lithiasis as an underlying cause and with an indication for drainage based on symptoms of or laboratory tests indicating infection and/or pain and/or kidney function.

Intervention: One group receives drainage by percutaneous nephrostomy catheter placement as opposed to the other group which will receive drainage by retrograde double J catheter placement.

Main study parameters/endpoints:

The primary objective is to assess whether a PCN is non-inferior to double J catheter regarding time to clinical recovery in patients with obstructive kidney disease resulting from urolithiasis.

The primary outcome parameter is time to clinical recovery. Clinical recovery is defined as reaching one or more of the following criteria. The mandatory amount of criteria to achieve clinical recovery is dependent on the indication for placement of a PCN or a JJ.

  • If indication for drainage is infection: improvement of infection, indicated by a decrease of WBC in two executive laboratory results and below 15.000 mm3 and a body temperature of 36-38.5 C. and/or
  • If indication for drainage is untreatable pain: Numeric rating score (NRS) considering pain resulting from a renal colic is improved and < 3 points and/or
  • If indication for drainage is deterioration of kidney function: improvement of creatinine/ Glomerular Filtration Rate (GFR) in two executive laboratory results It may occur that the indication for drainage is a combination of the above named indications. Clinical recovery will then be reached in case all parameters related to the different indications are within the set range. Secondary outcomes are further clinical data, PROMS (measured by the EQ-5D-5L, NRS, a satisfaction scale and a catheter questionnaire) and societal costs (measured by a diseasespecified iMCQ questionnaire).

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The placement of either PCN or double J catheter is standard care. Currently the choice for PCN or a double J catheter is based on expert opinion and may be driven by arguments considering logistics or assumptions about the quality of life for a patient after placement.

Considering the difference in rate of placement of both PCN and double J catheter between various hospitals and different countries, it is believed experts have no uniform work method to handle the dilemma of choosing between these two techniques.[2] Furthermore the current EAU-guideline 2018 states that both methods of drainage are to be considered as equal.[1] Therefore there is no reason to believe, patients will be affected negatively by being placed randomly in either the double J group or the PCN group. Questionnaires will be filled in daily during hospitalization and twice or less afterwards. This is not considered to be a risk for the patient. The longest questionnaires (EQ-5D-5L and iMCQ) will take approximately 10-20 minutes to fill in, additional to the shorter scales (NRS, satisfaction scale) which will take approximately 1 minute to fill in. Generally It will take 90 minutes, spread over the course of three months, to fill in all questionnaires. For frequency and timing of the questionnaires. Finally, no additional visits to a hospital, withdrawal of blood samples or exposure to radiation is to be expected when taking part in this study.

Being tested
Percutaneous Nephrostomy, Double J catheter
Keywords
Urolithiasis, Urologic Diseases, Urinary Calculi, Urinary Obstruction, Urinary Stone, Nephrostomy; Complications, Catheter Complications, double j catheter, JJ catheter, urinary stent, percutaneous nephrostomy, stent
Medical subject headings
Urolithiasis, Urologic Diseases, Urinary Calculi, Ureteral Obstruction, Ureterolithiasis, Nephrolithiasis, Kidney Calculi, Bites and Stings

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Percutaneous NephrostomyDevice

    Also called PCN, Nephrostomies, Percutaneous, Percutaneous Nephrostomies, Nephrostomy

    A Percutaneous Nephrostomy will be placed in patients with obstructive urolithiasis

  • Double J catheterDevice

    Also called stent, JJ, internal stent, JJ catheter

    A Double J catheter will be placed in patients with obstructive urolithiasis

Study groups in NCT04594161
Study groupRoleWhat they receive
Percutaneous NephrostomyActive comparatordrainage of the kidney by means of a percutaneous Nephrostomy
Receives: Device: Percutaneous Nephrostomy
Double J catheterActive comparatordrainage of the kidney by means of a double J catheter
Receives: Device: Double J catheter

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. time (hours) to clinical recovery regarding infection

    Unit is hours (0-∞), higher scores mean a worse outcome. Clinical recovery is defined as reaching one or more of the following criteria (all criteria are added seperately)

    • If indication for drainage is infection clinical recovery is defined as: improvement of infection, indicated by a decrease of WBC (unit: mm3) in two executive laboratory results and at least below 15.000 mm3.

    Measured: 3 months

  2. time (hours) to clinical recovery regarding infection

    Unit is hours (0-∞), higher scores mean a worse outcome. Clinical recovery is defined as reaching one or more of the following criteria (all criteria are added seperately)

    • If indication for drainage is infection clinical recovery is defined as: improvement of infection, indicated by a body temperatur between 36.0-38.5 °Celsius. and/or
    • If indication for drainage is untreatable pain: Numeric rating score (NRS) considering pain resulting from a renal colic is improved and < 3 points and/or
    • If indication for drainage is deterioration of kidney function: improvement of creatinine/ Glomerular Filtration Rate (GFR) in two executive laboratory results

    Measured: 3 months

  3. time (hours) to clinical recovery regarding pain

    Unit is hours (0-∞), higher scores mean a worse outcome. Clinical recovery is defined as reaching one or more of the following criteria (all criteria are added seperately) If indication for drainage is untreatable pain clinical recover is defined as: Numeric Rating Score (NRS) considering pain resulting from a renal colic is improved and < 3 points (higher scores mean greater level of pain).

    Measured: 3 months

  4. time (in hours) to clinical recovery regarding kidney function

    Unit is hours (0-∞), higher scores mean a worse outcome. Clinical recovery is defined as reaching one or more of the following criteria (all criteria are added seperately) If indication for drainage is deterioration of kidney function: improvement of creatinine (μmol/L) and/or Glomerular Filtration Rate (ml/min/1.73 m2) in two executive laboratory results.

    Measured: 3 months

Secondary outcomes (7)
  1. patient reported outcome measures (PROMS) quality of life

    EQ-5D-5L questionnaire (range 0-1; greater scores reflect a higher quality of life).

    Measured: 3 months

  2. patient reported outcome measures (PROMS) pain score

    Numeric Rating Score (NRS) considering pain questionnaire (range 0-10; greater scores reflect higher pain levels)

    Measured: 3 months

  3. patient reported outcome measures (PROMS) satisfaction

    satisfaction scale (range 0-10; greater scores reflect higher levels of satisfaction)

    Measured: 3 months

  4. patient reported outcome measures (PROMS) catheter related problems

    catheter questionnaire. All answers will be analysed using frequencies. No score is applicable.

    Measured: 3 months

  5. patient reported outcome measures (PROMS) cost and productivity

    disease-specified iMCQ (Medical Consumption Questionnaire)/iPCQ (Productivity Cost Questionnaire). All answers will be analyzed using frequencies and will be used in economical models to calculate productivity burden and societal and individual costs.

    Measured: 3 months

  6. patient reported outcome measures (PROMS) on costs iMCQ (Medical consumption questionnaire)

    disease-specified iMCQ (Medical Consumption Questionnaire). All answers will be analyzed using frequencies and will be used in economical models to calculate productivity burden and societal and individual costs.

    Measured: 3 months

  7. patient reported outcome measures (PROMS) productivity

    iPCQ (Productivity Cost Questionnaire). All answers will be analyzed using frequencies and will be used in economical models to calculate productivity burden and societal and individual costs.

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Oct 2020
  2. Study start15 Jul 2020
  3. Primary completion1 Jan 2024
  4. Study completion1 Jan 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomised controlled trial
Masking
None (open label)
Enrolment
204 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04594161
Sponsor's protocol ID
METC 2020_057
Other IDs
NL70822.058.19
Acronym
STONE
Status last verified
Feb 2024
First submitted
16 Jul 2020
Last updated
28 Feb 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Schuil HW, Hendriks N, El Alili M, Bosmans JE, Duijnhoven RG, Oskam BCH, Arends TJH, Duijvesz D, Horsch AD, van der Heij B, Tjiam I, van Overhage H, Lamers ABGN, van Delden OM, Scheepens W, Drossaerts JMA, d'Ancona FCH, Boering S, van Uhm JIM, van der Meer RW, van Roijen HJH, de Kiefte M, Hendrix AJM, Weltings S, Pelger RCM, Beerlage HP, Kamphuis GM, Schout BMA. Cost-effectiveness of percutaneous nephrostomy vs JJ stent in obstructive urolithiasis: economic evaluation alongside the STent Or NEphrostomy (STONE) randomised controlled trial. BJU Int. 2026 May;137(5):906-913. doi: 10.1111/bju.70218. Epub 2026 Mar 13.

    PubMed 41830115

Questions about this trial

What is this clinical trial studying?

A study testing Percutaneous Nephrostomy and Double J catheter in people with Urolithiasis and Urologic Diseases, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

time (hours) to clinical recovery regarding infection (time frame: 3 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04594161, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Feb 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in